The objective of this Environmental Scan was to retrieve and report on international drug program criteria and recommendations from international Health Technology Assessment (HTA) agencies (including from the United States, Europe, Australia, and New Zealand) for the reimbursement of direct oral anticoagulants (DOACs, i.e., apixaban, dabigatran, edoxaban, and rivaroxaban) for the prevention of stroke and systemic embolism in patients with atrial fibrillation. More specifically, this project aimed to determine whether certain risk stratification scores (including CHADS2, CHAD65, or CHA2DS2-VASc) are used as reimbursement criteria for DOACs for this indication.
A formal grey literature search was conducted. The websites of selected international HTA agencies and publicly funded drug plans were also searched for HTA listing recommendations and reimbursement criteria. In addition, the websites of the 10 largest private health insurers in the United States were also searched.
anticoagulants, atrial fibrillation, risk assessment, stroke, thromboembolism, cardiovascular, DOAC, DOACs, Strokes, Thromboembolisms, direct oral anti-coagulant, direct oral anti-coagulants, direct oral anticoagulant, direct oral anticoagulants, risk stratification